Physician profile
Keith Garrison
NPI 1245868637
$4,035.45
in general payments reported to CMS, 2019-2025
17 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $219 · 2024: $2,222 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681 · Travel and Lodging: $1,182 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.49 |
| Travel and Lodging | $1,181.52 |
| Education | $172.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $992.75 | 2024 | Fusion |
| Abbvie INC. | $923.82 | 2024-2025 | |
| Janssen Biotech, INC. | $594.98 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Cook Medical LLC | $365.23 | 2024-2025 | Fusion, Hemospray, Echotip Insight |
| Takeda Pharmaceuticals U.S.A., INC. | $261.99 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $232.04 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $156.17 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $152.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $95.05 | 2024-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Endoclot Sis |
| Pfizer INC. | $73.01 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $38.65 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $35.48 | 2023 | Dupixent |
| Boston Scientific Corporation | $34.11 | 2024-2025 | Wallflex Duodenal |
| Gilead Sciences, INC. | $29.10 | 2025 | |
| Mirum Pharmaceuticals, INC. | $21.02 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $15.53 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $14.46 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.